Featured Research

from universities, journals, and other organizations

Neuronal transport granules: Single occupancy vehicles

Date:
March 26, 2012
Source:
University of Medicine and Dentistry of New Jersey (UMDNJ)
Summary:
Protein precursors destined for the spiny extensions of neurons travel single file, according to a new study.

Protein precursors destined for the spiny extensions of neurons travel single file, according to a study by Sanjay Tyagi, PhD, and colleagues at the University of Medicine and Dentistry of New Jersey (UMDNJ).

The study recently was published in Proceedings of the National Academy of Sciences.

Proteins involved in transmissions at the axon tips and synapses of neurons travel there in precursor form (known as messenger RNA, or mRNA) as cargo of a structure known as a transport granule. "The idea is that the mRNAs located at the synapse will be translated [into protein] on demand," explains Tyagi, an associate professor in the Department of Medicine at UMDNJ-New Jersey Medical School and at the school's Public Health Research Institute. "And if more than one copy of a protein is required on site," Tyagi adds, "it can be produced from a single mRNA."

Some investigators have suggested that these mRNAs carpool with others in the same granule. But the study by Tyagi and colleagues shows that these mRNAs proceed single file, with only one mRNA per granule. Although it may seem more efficient to transport multiple mRNAs in a single trip, this may not allow the neuron the flexibility it needs for the proper formation and functioning of synapses.

An increased understanding of how these mRNAs are transported to synapses may help scientists unravel the longstanding mystery behind memory generation, which requires the formation of new synapses and the modification of old ones.


Story Source:

The above story is based on materials provided by University of Medicine and Dentistry of New Jersey (UMDNJ). Note: Materials may be edited for content and length.


Journal Reference:

  1. M. Batish, P. van den Bogaard, F. R. Kramer, S. Tyagi. Neuronal mRNAs travel singly into dendrites. Proceedings of the National Academy of Sciences, 2012; 109 (12): 4645 DOI: 10.1073/pnas.1111226109

Cite This Page:

University of Medicine and Dentistry of New Jersey (UMDNJ). "Neuronal transport granules: Single occupancy vehicles." ScienceDaily. ScienceDaily, 26 March 2012. <www.sciencedaily.com/releases/2012/03/120326132543.htm>.
University of Medicine and Dentistry of New Jersey (UMDNJ). (2012, March 26). Neuronal transport granules: Single occupancy vehicles. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2012/03/120326132543.htm
University of Medicine and Dentistry of New Jersey (UMDNJ). "Neuronal transport granules: Single occupancy vehicles." ScienceDaily. www.sciencedaily.com/releases/2012/03/120326132543.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins